The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
62
Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
Mds Pharma Services (Us), Inc
Tempe, Arizona, United States
Effect on the electrocardiographic QT interval corrected for heart rate (QTc) in healthy subjects
Time frame: Serial triplicate ECGs at -60, -40 and -20 minutes prior to dosing: at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 16 and 22.5 hours after dosing on Day 1 in each period
To assess the effects of BMS-708163 on other ECG endpoints (heart rate [HR], QRS and PR intervals), and changes in waveform morphology
Time frame: At -60, -40 and -20 minutes prior to dosing; at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 16 and 22.5 hours after dosing on Day 1 in each period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days